JPMorgan Chase & Co. Analysts Give Fresenius SE & Co. KGaA (FRA:FRE) a €33.30 Price Target

Fresenius SE & Co. KGaA (FRA:FRE – Get Rating) has been assigned a €33.30 ($35.05) price target by analysts at JPMorgan Chase & Co. in a research note issued to investors on Friday, Borsen Zeitung reports. JPMorgan Chase & Co.‘s target price suggests a potential downside of 0.06% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Warburg Research set a €51.00 ($53.68) target price on shares of Fresenius SE & Co. KGaA in a research report on Tuesday. Berenberg Bank set a €60.25 ($63.42) price target on shares of Fresenius SE & Co. KGaA in a report on Friday, April 29th. UBS Group set a €30.00 ($31.58) price target on shares of Fresenius SE & Co. KGaA in a report on Wednesday, March 16th. Deutsche Bank Rese… set a €36.00 ($37.89) price target on shares of Fresenius SE & Co. KGaA in a report on Thursday, May 5th. Finally, Jefferies Financial Group set a €40.00 ($42.11) price target on shares of Fresenius SE & Co. KGaA in a report on Thursday, March 31st.

Shares of FRE opened at €33.32 ($35.07) on Friday. The firm has a 50-day moving average price of €32.83 and a 200 day moving average price of €35.05. Fresenius SE & Co. KGaA has a 52-week low of €60.16 ($63.33) and a 52-week high of €80.00 ($84.21).

About Fresenius SE & Co. KGaA (Get Rating)

Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

See Also